2
EW icon

2Xideas’s Edwards Lifesciences EW Stock Holding History

2Xideas’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Sell
340,806
-11,271
-3% -$944K 13.27% 2
2026
Q1 		$28.2M Sell
352,077
-77,038
-18% -$6.35M 11.05% 2
2025
Q4 		$36.6M Sell
429,115
-57,142
-12% -$4.69M 10.25% 2
2025
Q3 		$37.8M Sell
486,257
-34,454
-7% -$2.69M 7.99% 4
2025
Q2 		$40.7M Buy
520,711
+330,127
+173% +$24.6M 7.01% 4
2025
Q1 		$13.8M Buy
190,584
+13,288
+7% +$951K 2.1% 11
2024
Q4 		$13.1M Sell
177,296
-46,786
-21% -$3.27M 1.76% 20
2024
Q3 		$14.8M Buy
224,082
+21,404
+11% +$1.56M 1.99% 14
2024
Q2 		$18.7M Buy
202,678
+6,170
+3% +$546K 2.34% 9
2024
Q1 		$18.8M Buy
196,508
+40,465
+26% +$3.4M 2.3% 10
2023
Q4 		$11.9M Buy
156,043
+18,652
+14% +$1.3M 1.28% 40
2023
Q3 		$9.52M Sell
137,391
-3,552
-3% -$285K 1.05% 54
2023
Q2 		$13.3M Sell
140,943
-898
-0.6% -$78K 1.27% 24
2023
Q1 		$11.7M Buy
141,841
+10,847
+8% +$853K 1.13% 34
2022
Q4 		$9.77M Buy
130,994
+26,203
+25% +$2.02M 1.03% 51
2022
Q3 		$8.66M Sell
104,791
-9,084
-8% -$874K 0.91% 50
2022
Q2 		$10.8M Sell
113,875
-9,492
-8% -$983K 0.99% 33
2022
Q1 		$14.5M Sell
123,367
-4,915
-4% -$551K 1.02% 28
2021
Q4 		$16.6M Buy
128,282
+21,148
+20% +$2.47M 1% 29
2021
Q3 		$12.1M Sell
107,134
-2,730
-2% -$312K 0.92% 24
2021
Q2 		$11.4M Buy
109,864
+12,741
+13% +$1.2M 1.02% 18
2021
Q1 		$8.12M Buy
97,123
+17,007
+21% +$1.44M 0.9% 48
2020
Q4 		$7.31M Buy
+80,116
New +$6.65M 0.91% 17

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

2Xideas's EW Position: Q2 2026 in Review

2Xideas reduced its Edwards Lifesciences (EW) stake by 3.2% in Q2 2026, selling an estimated $944K and leaving 340,806 shares worth $30.8M. The position accounts for 13.27% of the portfolio, ranked #2.

2Xideas first reported a position in EW in Q4 2020 and has held it in 23 quarters since. The position peaked at $40.7M in Q2 2025. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • 2Xideas held 340,806 shares of Edwards Lifesciences worth $30.8M as of Q2 2026.
  • 2Xideas sold 11,271 Edwards Lifesciences shares in Q2 2026, an estimated $944K.
  • Edwards Lifesciences made up 13.27% of 2Xideas's portfolio in Q2 2026, its #2 holding.
  • 2Xideas first reported a position in Edwards Lifesciences in Q4 2020 and has held it in 23 quarters since.
  • 2Xideas's Edwards Lifesciences position peaked at $40.7M in Q2 2025.
  • 1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on 2Xideas's 13F filing for Q2 2026, filed 14 Aug 2026.